Showing 4051-4060 of 8129 results for "".
- Treat the Whole Patient: Enhancing Care in Pediatric Alopecia Areatahttps://practicaldermatology.com/news/enhancing-care-for-pediatric-alopecia-patients/2471536/Understanding and treating pediatric alopecia areata (AA), and its impact on the emotional and social lives of children and young people, was the subject of a presentation by dermatologist Brittany Craiglow, MD, PhD, FAAD. Addr
- JAK Inhibitors, Low-Dose Naltrexone Touted as New Options for Nail Lichen Planushttps://practicaldermatology.com/news/JAK-Inhibitors-Low-Dose-Naltrexone-Touted-New-Options-Nail-Lichen-Planus/2471532/JAK inhibitors and low-dose naltrexone appear to be two game-changing options for treatment of nail lichen planus, Shari Lipner, MD, PhD, FAAD, said at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Dr. Lipner noted the activity of the JAK pathway in lic
- Closing Gaps: Takeda Enhances Diversity in Psoriasis Trialshttps://practicaldermatology.com/news/closing-gaps-takeda-enhances-diversity-in-psoriasis-trials/2471442/Takeda’s phase 3 psoriasis (PsO) clinical trials in the United States achieved success in enhancing racial and ethnic diversity among participants, according to new data from the manufacturer. Psoriasis affects over 7.5 millio
- TSC Reduces Tretinoin-Induced Skin Irritation: Pilot Studyhttps://practicaldermatology.com/news/tsc-reduces-tretinoin-induced-skin-irritation-pilot-study/2471409/A recent pilot study has shown that tetramethylhexadecenyl succinoyl cysteine (TSC) significantly reduces erythema and dryness caused by tretinoin application. These findings may offer a novel approach to minimizing the common adverse effects of tretinoin, potential
- Phase 1 Trial Shows Safety and Dosing Potential for Combo IL-13 Therapy for ADhttps://practicaldermatology.com/news/phase-1-trial-shows-safety-and-dosing-potential-for-combo-il-13-therapy-for-ad/2471401/Apogee Therapeutics has reported positive interim results from a Phase 1 trial evaluating APG990, a subcutaneous, extended half-life monoclonal antibody targeting OX40L, for inflammatory and immunological conditions such as atopic dermatitis (AD), according to a pre
- Study: AI Model Improves Hair Growth, Texturehttps://practicaldermatology.com/news/ai-model-improves-hair-growth-texture/2471394/An artificial intelligence (AI)-driven platform for customizing hair loss treatments significantly improved hair growth, scalp health, and hair texture in a 24-week study involving women with self-reported hair thinning. The st
- Positive Results Reported From Delgocitinib CHE Trial in Chinahttps://practicaldermatology.com/news/Positive-Results-Reported-Delgocitinib-CHE-Trial-China/2471379/Positive results were announced for the primary endpoint from the double-blind treatment period of the DELTA China phase 3 clinical trial with Anzupgo® (delgocitinib) 20mg/g cream, a topical pan-Janus kinase (JAK) inhibitor, for the potential treatment of Chinese adults and adolescents (aged 12 a
- Dr. Lebwohl: Don't Delay GPP Treatment for TB Testing or Skin Biopsyhttps://practicaldermatology.com/news/Dr-Lebwohl-Dont-Delay-GPP-Treatment-TB-Testing-Skin-Biopsy/2471222/Generalized pustular psoriasis (GPP) treatment should not be delayed while waiting for a tuberculosis screening, according to Mark Lebwohl, MD. Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Lebwohl recommended initiating spesolimab therapy immediately
- Dr. Armstrong Discusses Combination Therapies for Psoriasishttps://practicaldermatology.com/news/Dr-Armstrong-Discusses-Combination-Therapies-Psoriasis/2471212/The quality and variety of biologic therapeutic options available today should give dermatologists more confidence than ever in treating psoriasis, according to April Armstrong, MPH, MPH. Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Armstrong discuss
- Guselkumab Effective in Psoriasis Regardless of Prior Treatment History: Studyhttps://practicaldermatology.com/news/guselkumab-effective-regardless-of-prior-treatment-history-study/2471126/Guselkumab was effective at managing moderate-to-severe psoriasis over five years, regardless of baseline disease severity or treatment history, according to a post hoc analysis of the VOYAGE 1 and 2 trials. The study looked